AUG 23, 2021 5:00 AM PDT

A Safe and Effective Combination Therapy for Advanced Cancer

WRITTEN BY: Katie Kokolus

Immunotherapies are emerging as a promising strategy for the treatment of late-stage cancers which currently have minimal therapeutic options. Immune checkpoint inhibitors (ICIs) are a type of immunotherapy that block signals that would otherwise dampen the immune response. Nivolumab, an ICI used to treat many malignancies, including melanoma and kidney cancer, is commonly used in combination with other cancer therapies. 

The results of a multi-center phase 1 clinical trial recently published in Clinical Cancer Research demonstrated that combining nivolumab with entinostat, a histone deacetylase inhibitor drug, is a safe and effective strategy for treating patients with advanced cancer who have not responded to standard therapies. 

The study enrolled 33 patients with various solid tumors that had not responded to, on average, 3.5 previous therapeutic strategies. All patients received entinostat for two weeks. While continuing entinostat, patients received either nivolumab or nivolumab and a second ICI, ipilimumab.  

Adverse events associated with treatment were very mild and included symptoms like fatigue, nausea, and diarrhea. These minor side effects suggest that the combination therapy is safe and well-tolerated, an important consideration for physicians prescribing treatment for immunocompromised oncology patients.

Following treatment, the time to disease progression averaged 6.1 months. The average overall survival of patients in the study was 10.6 months. While 60% of the participants demonstrated clinical benefit, 44% achieved stable disease, indicating that the tumors stopped growing. One patient with triple-negative breast cancer had a complete response.  

The study team also evaluated the effects the treatment had on the immune response. Blood and tissue samples were collected three times throughout the study: before treatment, after two weeks of entinostat, and following ICI treatment. The ratio of CD8/FoxP3 increased following ICI treatment indicating a robust anti-tumor response. 

Specifically, these findings demonstrate that ICIs modulate two essential elements of anti-tumor immunity. First, cytotoxic CD8 T cells, the immune cells which directly kill cancer cells, are increased with ICI treatment.  Second, T regulatory cells, immune cells that regulate the immune system and suppress anti-tumor effects, are decreased with ICI treatment. 

This study highlights a unique therapeutic combination of a drug inhibitor and two ICIs. The findings encourage the need for additional trials testing combination therapies involving ICIs.  Further study could result in novel discoveries which will improve response rates in cancers that are currently untreatable.

Sources: ImmunotherapiesImmune checkpoint inhibitorsNivolumabClinical Cancer ResearchentinostatIpilimumab

 

About the Author
  • PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
JUN 14, 2021
Health & Medicine
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
JUN 14, 2021
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
Valued for stroke and heart attack prevention, aspirin is also recommended for colorectal cancer prevention. A Harv ...
JUN 14, 2021
Cell & Molecular Biology
Can An Omega-3 Fatty Acid Destroy Tumors?
JUN 14, 2021
Can An Omega-3 Fatty Acid Destroy Tumors?
The body needs fatty acts for a variety of functions, and the health benefits of taking fatty acid supplements have long ...
JUN 16, 2021
Cancer
New drug attacks pancreatic tumors with mutant KRAS addiction
JUN 16, 2021
New drug attacks pancreatic tumors with mutant KRAS addiction
Pancreatic cancer is notoriously difficult to detect in early stages, which is why it is associated with a low survival ...
JUL 12, 2021
Cell & Molecular Biology
A Molecule From the Gut Microbiome May Fight Tumors
JUL 12, 2021
A Molecule From the Gut Microbiome May Fight Tumors
The more we learn abut the gut microbiome, the more it seems that the microorganisms in our gastrointestinal tracts can ...
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
OCT 01, 2021
Health & Medicine
Eppendorf Award 2022: Call for Entries
OCT 01, 2021
Eppendorf Award 2022: Call for Entries
Eppendorf Award 2022: Call for Entries The Eppendorf Award for Young European Investigators, endowed with 20,000 EUR, is ...
Loading Comments...